VivoSeq
Other

Heart Transplant

1

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Heart Transplant is an early-stage landscape with 1 program across 5 companies. The most active players are AstraZeneca, Eli Lilly, Novartis. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

64/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Novartis logo

Novartis

0 programs

PreclinicalChong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Dapagliflozin

AstraZeneca

Approved
No programs

Analysis

Trial Status

19

clinical trials

Completed7 · 37%
Terminated4 · 21%
Unknown status3 · 16%
Recruiting3 · 16%
Not yet recruiting1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Allograft Dysfunction in Heart Transplant
Recruiting·—·Phase 4·NCT03102125·376 enrolled
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Recruiting·—·Phase 2/3·NCT07079735·150 enrolled
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
Recruiting·—·Phase 1/2·NCT04924491·11 enrolled
DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Active, not recruiting·OOslo University Hospital·Phase 3·NCT05321706·430 enrolled
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Not yet recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 4·NCT06942156·140 enrolled
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
Completed·Novartis logoNovartis·Phase 4·NCT00862979·162 enrolled
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
Completed·Novartis logoNovartis·Phase 4·NCT01266148·115 enrolled
Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients
Completed·—·Phase 3·NCT03231371·22 enrolled
Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
Completed·UUniversity Hospital, Limoges·Phase 4·NCT00812786·42 enrolled
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
Completed·Novartis logoNovartis·Phase 3·NCT00098007·199 enrolled
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
Completed·Roche logoRoche·Phase 4·NCT02554955·36 enrolled
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
Completed·RRabin Medical Center·Phase 4·NCT00596557·20 enrolled
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01795729·6 enrolled
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Terminated·MMassachusetts General Hospital·Phase 4·NCT03208244·40 enrolled
Multi-Drug Desensitization Protocol for Heart Transplant Candidates
Terminated·PProvidence Health & Services·Phase 2·NCT01556347·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)